Streetbeat News

Price Targets

ETNB

Over the past 3 months, 5 analysts have provided ratings for 89bio (NASDAQ:ETNB), with 2 being bullish and 3 somewhat bullish. There have been no indifferent, somewhat bearish, or bearish ratings. The average price target is now $29.0, down from the previous $32.33, which is still a significant upside from the current price of $7.922. Analysts typically review stocks quarterly and may adjust their predictions based on various financial metrics and company performance.

Portfolio Pulse from Benzinga Insights

November 28, 2023 | 1:00 pm

SLRN

Acelyrin (NASDAQ:SLRN) has received 5 analyst ratings in the last quarter, with 3 being bullish, 1 somewhat bullish, and 1 indifferent. The average 12-month price target for Acelyrin is $32.4, with a high of $44.00 and a low of $19.00, representing a 4.71% decrease from the previous target of $34.00. Analysts rate stocks based on research and provide guidance to investors, though their opinions are not infallible.

Portfolio Pulse from Benzinga Insights

November 28, 2023 | 1:00 pm

GMAB

Genmab (NASDAQ:GMAB) received 9 analyst ratings in the last quarter, with 8 being bullish and 1 somewhat bearish. The average 12-month price target for GMAB is $48.33, with a high of $54.00 and a low of $32.00. This target has increased by 13.26% over the past month, indicating a positive sentiment among analysts towards the stock.

Portfolio Pulse from Benzinga Insights

November 28, 2023 | 1:00 pm

IFF

Analysts have provided mixed ratings for Intl Flavors & Fragrances (NYSE:IFF) with 1 bullish, 1 somewhat bullish, 4 indifferent, and 1 somewhat bearish rating in the last quarter. The average price target is $76.14, slightly above the current price of $76.11, representing a marginal upside. This target is a 0.14% decrease from the previous target of $76.25.

Portfolio Pulse from Benzinga Insights

November 28, 2023 | 1:00 pm

MS

Societe Generale analyst Andrew Lim has downgraded Morgan Stanley (NYSE:MS) from Buy to Hold and set a price target of $80.

Portfolio Pulse from Benzinga Newsdesk

November 28, 2023 | 12:59 pm

IFF

Argus Research analyst John Eade has upgraded Intl Flavors & Fragrances (IFF) from Hold to Buy and set a price target of $85.

Portfolio Pulse from Benzinga Newsdesk

November 28, 2023 | 12:56 pm

MDLZ

Argus Research analyst Taylor Conrad has upgraded Mondelez International (NASDAQ:MDLZ) from Hold to Buy and set a price target of $83.

Portfolio Pulse from Benzinga Newsdesk

November 28, 2023 | 12:54 pm

BRNS

HC Wainwright & Co. analyst Yi Chen has reiterated a Buy rating on Barinthus Biotherapeutics (NASDAQ:BRNS) and maintained a $15 price target for the company's stock.

Portfolio Pulse from Benzinga Newsdesk

November 28, 2023 | 12:44 pm

ZS

Rosenblatt analyst Catharine Trebnick has reiterated a Buy rating on Zscaler (NASDAQ:ZS) and maintained a price target of $225.

Portfolio Pulse from Benzinga Newsdesk

November 28, 2023 | 12:42 pm

CIEN

Rosenblatt analyst Mike Genovese has reiterated a Buy rating on Ciena (NYSE:CIEN) and maintained a $65 price target for the company's stock.

Portfolio Pulse from Benzinga Newsdesk

November 28, 2023 | 12:40 pm